The Stupp video only confirms his assertion that rGBM is a major unmet need, but Dr. Jenkinson suggested that SOC would follow peer review of the data:
Also in reference to SOC, the Keytruda combo study is interesting and relevant:
The placebo group is receiving murcidencel as if it were already SOC for rGBM. For rGBM (recurrent) specifically, there is no SOC to extend life, so dosing the placebo group with murcidencel makes sense.
Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus murcidencel in combo at UCLA, skip to minute 45:40
NCI, Merck, & PHASE ONE are today supporting collaborators on the UCLA Keytruda trial—100% of patients in both the experimental group AND the placebo group receive murcidencel. Only Keytruda in combo is being investigated.
Group A (pembrolizumab, ATL-DC, poly ICLC) Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
Group B (placebo, ATL-DC, poly ICLC) Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
News 
Market Data 
Discover 
AI
